MicroRNAs and lymphomas

C. M. Croce

1Ohio State University, Comprehensive Cancer Center, Columbus, OH, USA

MicroRNAs (miRNAs) are small non-coding RNAs which regulate the expression of target mRNAs through base pairing to partially (in mammals) or perfectly (in plants) complementary sites, mainly, but not exclusively, in the 3'-untranslated region (3'-UTR) of their targets [1]. Should a perfect complementarity occur, the miRNA is cleaved and degraded, whereas a translational silencing is the main miRNA regulatory mechanism in the case of imperfect base pairing [1].

MiRNAs have important regulatory functions, including cell cycle, apoptosis and differentiation [2]. Systematic miRNA expression profiling has revealed widespread aberrant miRNA expression in cancer with respect to the normal tissues, including lymphomas [3–6].

Earlier studies have shown that miR-155 is up-regulated in pediatric Burkitt’s lymphoma [4], diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBL) and Hodgkin’s lymphoma [5–6] (Table 1). This miRNA is encoded by the final portion of the BIC (B-cell integration cluster) gene, which was originally identified as a common retroviral integration site in avian leukosis virus-induced B-cell lymphomas [7]. Our group demonstrated that mice overexpressing miR-155 in B lymphocytes develop polyclonal pre-leukemic pre-B-cell proliferation followed by full-blown B-cell malignancy [8]. More recently two knock-out mice models have demonstrated a critical role of miR-155 in immunity by showing that BIC/miR-155–/– have defective dendritic cell functions, impaired cytokine secretion and T H cells intrinsically biased toward T H2 differentiation [9–10]. Moreover miR-155 could represent the connection between inflammation, immunity and cancer since its expression can be induced by mediators of the inflammasome and is involved in the response to endotoxic shock [11].

He et al. [12] reported that the miR-17–92 polycistron, which is located in 13q31–32, a region commonly amplified in B-cell lymphoma12, was up-regulated in 65% of the B-cell lymphoma patients. The authors overexpressed the miR-17–92 cluster in HPCs from mice that carry the MYC transgene and reported that the miR-17–92 cluster acted, together with MYC expression, to accelerate tumor development [12]. A different group recently generated mice with high miR-17–92 expression in lymphocytes and found that these mice developed a lymphoproliferative disease and autoimmunity and died prematurely (Table 1) [13]. The transgenic lymphocytes exhibited enhanced proliferation and survival due to the down-regulation of PTEN and the pro-apoptotic Bim (which controls B-lymphocyte apoptosis) by the miR-17–92 cluster [13].

Insights about the regulation of this cluster in lymphoma was provided by O’Donnell et al. [14]. Using an inducible system of MYC expression and ChIP assays, the authors showed that MYC binds and activates the expression of the miR-17–92 cluster at chromosome 13q31. Furthermore, they indicated that E2F transcription factor 1 (E2F1) is down-regulated by two miRNAs of the cluster, miR-17–5p and miR-20a. E2F1 is a direct target of MYC that promotes cell-cycle progression [15]. Thus, MYC simultaneously activates E2F1 and limits its translation through a miRNA-based mechanism, enabling a tightly controlled proliferative signal [14].

**Table 1.**

<table>
<thead>
<tr>
<th>MicroRNA</th>
<th>Genomic location</th>
<th>Expression in patients</th>
<th>Experimental data</th>
<th>Refs</th>
</tr>
</thead>
<tbody>
<tr>
<td>miR-155</td>
<td>21q21</td>
<td>Up-regulated in DLBCL, Hodgkin, pediatric Burkitt’s</td>
<td>Induces lymphoproliferation, pre-B lymphoma/leukemia in mice</td>
<td>28, 41–44</td>
</tr>
<tr>
<td>miR-17–92 cluster</td>
<td>13q14</td>
<td>Up-regulated in lymphomas</td>
<td>Cooperates with MYC; targets E2F1, Bim and PTEN</td>
<td>45–47</td>
</tr>
</tbody>
</table>

The author reports no relationships with companies whose products or services are mentioned in this manuscript.

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org


